

# Varun Beverages

Refer to important disclosures at the end of this report

## Strong Q1 leads to earnings upgrade; maintain Buy

<b>CMP</b>	<b>Target Price</b>
Rs 1,060 as of (April 28, 2022)	Rs 1,230 (▲) 12 months
<b>Rating</b>	<b>Upside</b>
BUY (■)	16.1 %

- Q1 EBITDA was 11-19% higher than our/Street estimates, led by an 8-10% revenue beat and high margins. Topline grew 26%, led by 19%/6% volume/realization growth. A 430bps RM spike was offset by operating leverage, leading to 180bps EBITDA margin gains.
- VBL expects growth momentum to continue thanks to a strong demand environment and its investments in the distribution channel. VBL does not expect gross margins to decline further in CY22, led by sufficient PET reserves and sugar prices remaining range-bound.
- Net debt remained flat at Rs31bn but VBL expects a ~40% reduction in CY22. With strong growth trends in Zimbabwe, VBL plans to invest ~USD15mn to expand capacity in CY22. Total capex is expected to be relatively lower in CY22 vs. Rs8.5bn in CY21.
- We raise EPS estimates by 5-7% on the Q1 beat. Sustained momentum strengthens our confidence in VBL's ability to achieve our higher-than-consensus estimates. Retain Buy with a revised Jun'23 TP of Rs1,230 (based on 33x Jun'24 EPS vs. 34x Mar'24 earlier).

**Strong broad-based momentum continues:** VBL reported ~26% revenue growth, driven by ~19%/6% volume/realization. Among geos, India volumes grew strongly at ~17% and Intl. volume growth was even better at ~30%. India growth was led by both 1) strong traction in new launches Sting/Dairy/Juices (~10% volume mix vs. negligible mix in Q1CY19) and 2) healthy traction in the existing portfolio. While all Intl. geos saw healthy growth trends, Morocco was incrementally helped by the ramp-up of its new water line. Encouragingly, volume growth was broad-based with Carbonates growing in line with fast-growing Juice/Water categories at ~18-21%. Realization improvement was led by price hikes in select SKUs, mix improvement and higher realization growth in Intl. geos. Going ahead, VBL expects strong demand trends to continue, helped by industry-wide growth momentum and VBL's investments in distribution/chilling equipment in acquired territories.

**Operating leverage helped VBL offset high RM inflation:** Gross margins declined ~430bps to 51.5%, due to a ~30% increase in prices for PET chips (~15% of sales). Other raw materials (Sugar/Concentrates; ~30% of sales) remain range-bound. However, operating leverage and lower asset write-off (Rs140mn vs. Rs360mn YoY) helped VBL more than offset the decline in gross margins, leading to ~180bps EBITDA margin improvement. Going ahead, VBL expects pre-stocking of PET to offset any incremental impact of inflation in CY22E.

**Healthy long-term potential; maintain Buy:** Sustained momentum strengthens our confidence in VBL's ability to achieve our estimates, which are ~10% higher than consensus. Potential share gains, best-in-class efficiencies and consistent improvement in the RoIC profile keep us positive. Maintain Buy with a revised TP of Rs1,230 (based on 33x Jun'24E EPS vs. 34x Mar'24E earlier). The reduction in the multiple was due to 3M rollover and 25bps higher CoE assumption.

Please see our sector model portfolio (Emkay Alpha Portfolio): [Consumer Goods & Retail \(Page 8\)](#)


<b>Change in Estimates</b>	
EPS Chg CY22E/CY23E (%)	6/5
Target Price change (%)	7.0
Target Period (Months)	12
Previous Reco	BUY

<b>Emkay vs Consensus</b>		
<b>EPS Estimates</b>		
	<b>CY22E</b>	<b>CY23E</b>
Emkay	26.4	33.8
Consensus	23.8	28.7
Mean Consensus TP (12M)	Rs 1,105	

<b>Stock Details</b>	
Bloomberg Code	VBL IN
Face Value (Rs)	10
Shares outstanding (mn)	433
52 Week H/L	1,147 / 603
M Cap (Rs bn/USD bn)	459 / 6.00
Daily Avg Volume (nos.)	652,736
Daily Avg Turnover (US\$ mn)	8.3

<b>Shareholding Pattern Mar '22</b>	
Promoters	64.9%
FIIIs	21.0%
DIIIs	7.2%
Public and Others	6.9%

<b>Price Performance</b>				
(%)	<b>1M</b>	<b>3M</b>	<b>6M</b>	<b>12M</b>
<b>Absolute</b>	13	20	29	69
<b>Rel. to Nifty</b>	13	19	33	45



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

**Devanshu Bansal**  
devanshu.bansal@emkayglobal.com  
+91 22 6612 1385

**Jigisha Kapoor**  
jigisha.kapoor@emkayglobal.com  
+91 22 6612 1314


### Financial Snapshot (Consolidated)

(Rs mn)	CY20	CY21	CY22E	CY23E	CY24E
Net Sales	64,501	88,232	1,15,648	1,31,765	1,49,832
EBITDA	12,019	16,546	23,726	27,747	32,250
EBITDA Margin (%)	18.6	18.8	20.5	21.1	21.5
APAT	3,223	6,941	11,416	14,645	17,736
EPS (Rs)	7.4	16.0	26.4	33.8	41.0
EPS (% chg)	(33.7)	115.3	64.5	28.3	21.1
ROE (%)	9.4	18.3	25.1	26.0	25.5
P/E (x)	142.4	66.1	40.2	31.3	25.9
EV/EBITDA (x)	40.9	29.7	20.2	16.9	14.2
P/BV (x)	13.0	11.2	9.1	7.4	6.0

Source: Company, Emkay Research


# Story in Charts

**Exhibit 1: Strong momentum continued with ~26% revenue growth; Expect Q2 to see strong growth, post lockdowns over last two years**




Source: Company, Emkay Research

**Exhibit 2: EBITDA margins increased ~180bps led by higher realization and operating leverage from increased sales volume**




Source: Company, Emkay Research

**Exhibit 3: 26% revenue CAGR was driven by 19% volume CAGR and 6% realization CAGR**




Source: Company, Emkay Research

**Exhibit 4: Both domestic and international geographies saw healthy volume growth in Q4CY21**




Source: Company, Emkay Research

**Exhibit 5: Consol margins were higher than standalone margins**




Source: Company, Emkay, \*Considered standalone margins as India margins

**Exhibit 6: VBL 1-yr fwd P/E chart**




Source: Company, Emkay Research

**Exhibit 7: FCF generation should improve with strong operating performance and relatively low capex requirements**



Source: Company, Emkay Research

**Exhibit 8: Asset turnover improvement should lead to continued improvement in RoIC**



Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 04/29/2022 05:57 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## Exhibit 9: Actual vs. Estimates (Q1CY22)

(Rs mn)	Actual	Estimates		% variation		Comments
		Emkay	Consensus	Emkay	Consensus	
Net Sales	28,275	25,600	26,260	10%	8%	Higher realizations and volumes led to revenue beat
EBITDA	5,310	4,455	4,778	19%	11%	EBITDA margins improved 180bps, led by operating leverage
EBITDA Margin (%)	18.8%	17.4%	18.2%	138 bps	58 bps	
PAT	2,542	1,902	2,131	34%	19%	Better operating performance led to PAT beat

Source: Company, Emkay Research

## Exhibit 10: Summary of quarterly results

Rs mn	Q1CY21	Q2CY21	Q3CY21	Q4CY21	Q1CY22	YoY%	QoQ%	CY22TD	CY21TD	YoY%
Sales	22,409	24,498	23,982	17,343	28,275	26.2	63.0	28,275	22,409	26.2
Cost of Revenue	9,902	11,383	11,324	7,738	13,702	38.4	77.1	13,702	9,902	38.4
as % of sales	44.2	46.5	47.2	44.6	48.5			48.5	44.2	
Employee Cost	2,384	2,432	2,662	2,598	2,751	15.4	5.9	2,751	2,384	15.4
as % of sales	10.6	9.9	11.1	15.0	9.7			9.7	10.6	
Other Expenses	6,307	4,975	5,049	4,931	6,512	3.3	32.1	6,512	6,307	3.3
as % of sales	28.1	20.3	21.1	28.4	23.0			23.0	28.1	
Total Expenditure	18,593	18,790	19,035	15,268	22,965	23.5	50.4	22,965	18,593	23.5
EBITDA	3,816	5,708	4,947	2,076	5,310	39.1	155.8	5,310	3,816	39.1
Depreciation	1,347	1,288	1,385	1,293	1,313	-2.5	1.6	1,313	1,347	-2.5
EBIT	2,469	4,420	3,562	783	3,997	61.9	410.5	3,997	2,469	61.9
Other Income	57	244	369	9	85	48.5	896.3	85	57	48.5
Interest cost	579	468	427	373	470	-19.0	25.9	470	579	-19.0
PBT	1,947	4,197	3,504	419	3,612	85.5	763.1	3,612	1,947	85.5
Tax	579	1,009	925	93	901	55.6	872.9	901	579	55.6
PAT before Minority	1,368	3,188	2,579	326	2,711	98.2	731.8	2,711	1,368	98.2
Minority Interest	-75	-106	-178	-161	-169	125.0	4.9	-169	-75	125.0
Exceptional Items	0	0	0	0	0			0	0	
Reported PAT	1,293	3,082	2,401	165	2,542	96.7	1,441.5	2,542	1,293	96.7
Reported EPS (Rs)	3.0	7.1	5.5	0.4	5.9	96.7	1,441.5	5.9	3.0	96.7

Margins (%)	Q1CY21	Q2CY21	Q3CY21	Q4CY21	Q1CY22	YoY bps	QoQ bps	CY22TD	CY21TD	YoY%
EBIDTA	17.0	23.3	20.6	12.0	18.8	180.0	680.0	18.8	17.0	149.5
EBIT	11.0	18.0	14.9	4.5	14.1	310.0	960.0	14.1	11.0	236.4
PBT	8.7	17.1	14.6	2.4	12.8	410.0	1040.0	12.8	8.7	326.8
PAT	6.1	13.0	10.8	1.9	9.6	350.0	770.0	9.6	6.1	375.3
Effective Tax rate	29.8	24.0	26.4	22.1	25.0	-480.0	280.0	25.0	29.8	65.0

Source: Company, Emkay Research

## Exhibit 11: Changes in estimates

Rs mn	CY22E			CY23E			CY24E		
	Old	New	% change	Old	New	% change	Old	New	Change (%)
Revenues	1,11,251	1,15,648	4.0	1,26,039	1,31,765	4.5	1,42,495	1,49,832	5.1
EBITDA	22,345	23,726	6.2	26,428	27,747	5.0	30,398	32,250	6.1
EBITDA margins, %	20.1	20.5	40 bps	21.0	21.1	10 bps	21.3	21.5	20 bps
Net profits	10,748	11,416	6.2	13,948	14,645	5.0	16,637	17,736	6.6
EPS (Rs)	24.8	26.4	6.2	32.2	33.8	5.0	38.4	41.0	6.6

Source: Company, Emkay Research

## Exhibit 12: Key assumptions

Particulars	CY16	CY17	CY18	CY19	CY20	CY21	CY22E	CY23E	CY24E
CSD* (mn cases)	223	220	257	347	309	400	507	558	609
JNSD** (mn cases)	16	14	22	33	26	36	55	64	72
Water (mn cases)	38	44	61	111	90	132	169	193	215
<b>Total Volume (mn cases)</b>	<b>277</b>	<b>278</b>	<b>340</b>	<b>491</b>	<b>425</b>	<b>568</b>	<b>730</b>	<b>815</b>	<b>896</b>
Revenue/Case (Rs)	140	143	150	145	152	155	158	162	167
EBITDA/Case (Rs)	29	30	30	29	28	29	33	34	36

Source: Company, Emkay Research, \*CSD is carbonated soft drinks, \*\*JNSD is juices, nectars and still drinks

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 04/29/2022 05:57 PM

**Exhibit 13: Expect VBL to deliver ~15% revenue CAGR over CY19-35E, led by 11% growth in per capita consumption (PCC), population increase, price hikes and market share gains**

VBL growth build-up	CAGR			Range		
	CY19	CY35E	(%)	Down	Base	Up
<b>PCC (L)</b>	<b>18.4</b>	<b>100.0</b>	<b>11.2</b>	<b>10.2</b>	<b>11.2</b>	<b>12.2</b>
Population (bn)	1.4	1.5	0.5	0.3	0.5	0.7
<b>Pepsi market share (%)</b>	<b>30.0</b>	<b>40.0</b>	<b>1.8</b>	<b>1.3</b>	<b>1.8</b>	<b>2.3</b>
<b>Realization growth (%)</b>			<b>1.5</b>	<b>1.5</b>	<b>1.5</b>	<b>2.0</b>
[A] Product mix			0.0	0.0	0.0	0.5
[B] Price hike			1.5	1.5	1.5	1.5
<b>Total Revenue CAGR (%)</b>				<b>13.3</b>	<b>14.9</b>	<b>17.1</b>

Source: Company, Emkay Research

**Exhibit 14: Target multiple for Varun Beverages derived from a two-stage dividend growth model**

Revenue CAGR [CY21-24E] (%)	19.3
EPS CAGR [CY21E-24E] (%)	36.7
<b>Stage-1: CY24E-34E</b>	
EPS in Yr-0 [CY24E] (Rs)	41
EPS in Yr-1 (Rs)	47
EPS CAGR (%)	15.0
Years of growth [n]	10.0
RoE (%)	25.0
CoE (%)	10.5
Implied DPR (%)	40
<b>Terminal stage: &gt;CY34E</b>	
<b>EPS growth (%)</b>	<b>6.0</b>
RoE (%)	25.0
Implied DPR (%)	76
<b>Fair value P/E in Mar'25E (x)</b>	<b>27.6</b>
<b>Fair value in Mar'25E (x)</b>	<b>1,298</b>
<b>Fair value in Jun'23E (x)</b>	<b>1,118</b>
NPV of dividends in Jun'22E-25E (Rs/share)	17
<b>Overall fair value in Jun'23E (Rs/share)</b>	<b>1,135</b>
Jun'24E EPS (Rs)	37
<b>Implied target P/E in Jun'23E (x)</b>	<b>30</b>
Premium (%) [a]	10
<b>Implied target P/E in Jun'23E (x)</b>	<b>33</b>
<b>Implied TP in Mar'23E (Rs)</b>	<b>1,230</b>
CMP (Rs/share)	1,064
<b>Upside (%)</b>	<b>16</b>

Source: Emkay Research, [a] Revenue growth is likely to be front-loaded than assumed

**Key Financials (Consolidated)****Income Statement**

Y/E Dec (Rs mn)	CY20	CY21	CY22E	CY23E	CY24E
<b>Net Sales</b>	<b>64,501</b>	<b>88,232</b>	<b>1,15,648</b>	<b>1,31,765</b>	<b>1,49,832</b>
<b>Expenditure</b>	<b>52,483</b>	<b>71,686</b>	<b>91,922</b>	<b>1,04,018</b>	<b>1,17,582</b>
<b>EBITDA</b>	<b>12,019</b>	<b>16,546</b>	<b>23,726</b>	<b>27,747</b>	<b>32,250</b>
Depreciation	5,287	5,313	5,841	6,261	6,771
<b>EBIT</b>	<b>6,732</b>	<b>11,234</b>	<b>17,885</b>	<b>21,486</b>	<b>25,479</b>
Other Income	370	679	550	650	300
Interest expenses	2,811	1,847	2,274	1,474	716
<b>PBT</b>	<b>4,290</b>	<b>10,066</b>	<b>16,161</b>	<b>20,662</b>	<b>25,063</b>
Tax	784	2,606	4,121	5,269	6,391
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
<b>Reported Net Income</b>	<b>3,223</b>	<b>6,941</b>	<b>11,416</b>	<b>14,645</b>	<b>17,736</b>
<b>Adjusted PAT</b>	<b>3,223</b>	<b>6,941</b>	<b>11,416</b>	<b>14,645</b>	<b>17,736</b>

**Balance Sheet**

Y/E Dec (Rs mn)	CY20	CY21	CY22E	CY23E	CY24E
Equity share capital	2,887	4,330	4,330	4,330	4,330
Reserves & surplus	32,353	36,469	45,936	57,983	72,254
<b>Net worth</b>	<b>35,240</b>	<b>40,799</b>	<b>50,267</b>	<b>62,313</b>	<b>76,585</b>
<b>Minority Interest</b>	<b>648</b>	<b>1,168</b>	<b>1,168</b>	<b>1,168</b>	<b>1,168</b>
<b>Loan Funds</b>	<b>34,216</b>	<b>35,511</b>	<b>26,271</b>	<b>16,307</b>	<b>6,703</b>
Net deferred tax liability	2,259	3,111	3,423	3,765	4,141
<b>Total Liabilities</b>	<b>72,363</b>	<b>80,590</b>	<b>81,128</b>	<b>83,553</b>	<b>88,597</b>
<b>Net block</b>	<b>64,086</b>	<b>63,108</b>	<b>64,266</b>	<b>65,005</b>	<b>68,234</b>
<b>Investment</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Current Assets</b>	<b>19,829</b>	<b>27,745</b>	<b>35,419</b>	<b>39,622</b>	<b>44,259</b>
Cash & bank balance	1,900	3,366	5,799	6,205	6,585
Other Current Assets	0	0	0	0	0
<b>Current liabilities &amp; Provision</b>	<b>12,221</b>	<b>15,229</b>	<b>18,557</b>	<b>21,074</b>	<b>23,896</b>
<b>Net current assets</b>	<b>7,609</b>	<b>12,516</b>	<b>16,861</b>	<b>18,548</b>	<b>20,364</b>
Misc. exp	0	0	0	0	0
<b>Total Assets</b>	<b>72,363</b>	<b>80,590</b>	<b>81,128</b>	<b>83,553</b>	<b>88,597</b>

**Cash Flow**

Y/E Dec (Rs mn)	CY20	CY21	CY22E	CY23E	CY24E
<b>PBT (Ex-Other income) (NI+Dep)</b>	<b>4,357</b>	<b>10,066</b>	<b>16,161</b>	<b>20,662</b>	<b>25,063</b>
Other Non-Cash items	0	0	0	0	0
Chg in working cap	(394)	(3,442)	(1,913)	(1,281)	(1,435)
<b>Operating Cashflow</b>	<b>10,711</b>	<b>12,031</b>	<b>18,553</b>	<b>22,190</b>	<b>25,100</b>
Capital expenditure	(4,613)	(8,632)	(2,034)	(7,000)	(10,000)
<b>Free Cash Flow</b>	<b>6,098</b>	<b>3,399</b>	<b>16,520</b>	<b>15,190</b>	<b>15,100</b>
Investments	0	0	0	0	0
Other Investing Cash Flow	0	0	0	0	0
<b>Investing Cashflow</b>	<b>(4,613)</b>	<b>(8,632)</b>	<b>(2,034)</b>	<b>(7,000)</b>	<b>(10,000)</b>
Equity Capital Raised	(271)	221	0	0	0
Loans Taken / (Repaid)	(2,156)	1,250	(10,000)	(10,000)	(10,000)
Dividend paid (incl tax)	(722)	(1,083)	(1,949)	(2,598)	(3,464)
Other Financing Cash Flow	52	(474)	135	(712)	(540)
<b>Financing Cashflow</b>	<b>(5,909)</b>	<b>(1,933)</b>	<b>(14,087)</b>	<b>(14,784)</b>	<b>(14,720)</b>
<b>Net chg in cash</b>	<b>190</b>	<b>1,466</b>	<b>2,433</b>	<b>406</b>	<b>380</b>
Opening cash position	1,711	1,901	3,366	5,799	6,205
<b>Closing cash position</b>	<b>1,900</b>	<b>3,366</b>	<b>5,799</b>	<b>6,205</b>	<b>6,585</b>

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 04/29/2022 05:57 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY&lt;GO&gt;. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

**Key Ratios**

<b>Profitability (%)</b>	<b>CY20</b>	<b>CY21</b>	<b>CY22E</b>	<b>CY23E</b>	<b>CY24E</b>
EBITDA Margin	18.6	18.8	20.5	21.1	21.5
EBIT Margin	10.4	12.7	15.5	16.3	17.0
Effective Tax Rate	18.3	25.9	25.5	25.5	25.5
Net Margin	5.4	8.5	10.4	11.7	12.5
ROCE	9.8	15.6	22.8	26.9	29.9
ROE	9.4	18.3	25.1	26.0	25.5
RoIC	9.6	15.8	24.2	28.1	32.0

<b>Per Share Data (Rs)</b>	<b>CY20</b>	<b>CY21</b>	<b>CY22E</b>	<b>CY23E</b>	<b>CY24E</b>
EPS	7.4	16.0	26.4	33.8	41.0
CEPS	19.7	28.3	39.9	48.3	56.6
BVPS	81.4	94.2	116.1	143.9	176.9
DPS	1.7	2.5	4.5	6.0	8.0

<b>Valuations (x)</b>	<b>CY20</b>	<b>CY21</b>	<b>CY22E</b>	<b>CY23E</b>	<b>CY24E</b>
PER	142.4	66.1	40.2	31.3	25.9
P/CEPS	53.9	37.4	26.6	21.9	18.7
P/BV	13.0	11.2	9.1	7.4	6.0
EV / Sales	7.6	5.6	4.1	3.6	3.1
EV / EBITDA	40.9	29.7	20.2	16.9	14.2
Dividend Yield (%)	0.2	0.2	0.4	0.6	0.8

<b>Gearing Ratio (x)</b>	<b>CY20</b>	<b>CY21</b>	<b>CY22E</b>	<b>CY23E</b>	<b>CY24E</b>
Net Debt/ Equity	0.9	0.8	0.4	0.2	0.0
Net Debt/EBIDTA	2.7	1.9	0.9	0.4	0.0
Working Cap Cycle (days)	32.3	37.9	34.9	34.2	33.6

<b>Growth (%)</b>	<b>CY20</b>	<b>CY21</b>	<b>CY22E</b>	<b>CY23E</b>	<b>CY24E</b>
Revenue	(9.5)	36.8	31.1	13.9	13.7
EBITDA	(17.0)	37.7	43.4	16.9	16.2
EBIT	(29.8)	66.9	59.2	20.1	18.6
PAT	(31.3)	115.3	64.5	28.3	21.1

<b>Quarterly (Rs mn)</b>	<b>Q1CY21</b>	<b>Q2CY21</b>	<b>Q3CY21</b>	<b>Q4CY21</b>	<b>Q1CY22</b>
Revenue	22,409	24,498	23,982	17,343	28,275
EBITDA	3,816	5,708	4,947	2,076	5,310
<b>EBITDA Margin (%)</b>	<b>17.0</b>	<b>23.3</b>	<b>20.6</b>	<b>12.0</b>	<b>18.8</b>
PAT	1,293	3,082	2,401	165	2,542
<b>EPS (Rs)</b>	<b>3.0</b>	<b>7.1</b>	<b>5.5</b>	<b>0.4</b>	<b>5.9</b>

Source: Company, Emkay Research

<b>Shareholding Pattern (%)</b>	<b>Mar-21</b>	<b>Jun-21</b>	<b>Sep-21</b>	<b>Dec-21</b>	<b>Mar-22</b>
Promoters	66.4	65.8	64.9	64.9	64.9
FIs	20.3	20.7	21.7	21.2	21.0
DIs	5.9	5.8	6.8	7.1	7.2
Public and Others	7.4	7.6	6.6	6.8	6.9


Source: Capitaline

**RECOMMENDATION HISTORY TABLE**

Date	Closing Price	TP	Period (months)	Rating	Analyst
08-Apr-22	962	1,150	12m	Buy	Devanshu Bansal
20-Mar-22	949	1,150	12m	Buy	Devanshu Bansal
04-Feb-22	950	1,150	12m	Buy	Devanshu Bansal
29-Oct-21	849	1,120	12m	Buy	Devanshu Bansal
22-Sep-21	916	1,120	12m	Buy	Devanshu Bansal
03-Aug-21	789	915	12m	Buy	Devanshu Bansal
03-May-21	669	747	12m	Buy	Devanshu Bansal
17-Feb-21	630	687	12m	Buy	Devanshu Bansal
04-Nov-20	449	583	12m	Buy	Devanshu Bansal
05-Aug-20	498	567	12m	Buy	Devanshu Bansal
08-Jun-20	414	567	12m	Buy	Devanshu Bansal

Source: Company, Emkay Research

**RECOMMENDATION HISTORY CHART**



Source: Bloomberg, Company, Emkay Research

## Emkay Alpha Portfolio – Consumer Goods & Retail

### EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight based on Current NAV	Change vs last published EAP (bps)
<b>Consumer Goods &amp; Retail</b>	<b>10.17</b>	<b>10.17</b>	<b>0%</b>	<b>0</b>	<b>100.00</b>	
Asian Paints	1.41	0.61	-57%	-80	5.98	0
Berger Paints	0.17	0.00	-100%	-17	0.00	0
Britannia Industries	0.39	0.42	8%	3	4.17	0
Colgate-Palmolive	0.22	0.23	5%	1	2.24	0
Dabur India	0.32	0.33	1%	0	3.21	0
Emami	0.10	0.09	-6%	-1	0.91	0
Godrej Consumer Products	0.30	0.26	-12%	-3	2.58	0
Hindustan Unilever	1.90	1.14	-40%	-76	11.23	0
ITC	2.24	2.42	8%	18	23.76	0
Marico	0.27	0.30	10%	3	2.94	0
Nestle India	0.65	0.29	-55%	-36	2.85	0
Pidilite Industries	0.37	0.00	-100%	-37	0.00	0
Radico Khaitan	0.00	0.19	NA	19	1.91	0
United Breweries	0.10	0.44	325%	33	4.29	0
United Spirits	0.00	0.24	NA	24	2.32	0
Varun Beverages	0.15	0.26	72%	11	2.57	0
Aditya Birla Fashion & Retail	0.09	0.15	69%	6	1.52	0
Devyani International	0.00	0.19	NA	19	1.89	0
Jubilant FoodWorks	0.20	0.20	1%	0	2.00	0
Page Industries	0.26	0.58	123%	32	5.67	0
Titan Company	1.03	1.23	19%	20	12.11	0
TCNS Clothing	0.00	0.25	NA	25	2.48	0
Westlife Development	0.00	0.34	NA	34	3.36	0
<b>Cash</b>	<b>0.00</b>	<b>0.00</b>	<b>NA</b>	<b>0</b>	<b>0.00</b>	<b>0</b>

Source: Emkay Research

■ High Conviction/Strong Over Weight ■ High Conviction/Strong Under Weight

### Sector portfolio NAV

	Base					Latest
	1-Apr-19	27-Apr-21	27-Oct-21	27-Jan-22	28-Mar-22	27-Apr-22
EAP - Consumer Goods & Retail	100.0	119.9	149.0	139.3	140.8	146.4
BSE200 Neutral Weighted Portfolio (ETF)	100.0	115.4	135.6	128.1	127.1	132.9

\*Performance measurement base date 1st April 2019


Source: Emkay Research

### Price Performance (%)

	1m	3m	6m	12m
EAP - Consumer Goods & Retail	4.0%	5.1%	-1.7%	22.2%
BSE200 Neutral Weighted Portfolio (ETF)	4.5%	3.7%	-2.0%	15.1%

Source: Emkay Research

### NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): [Nifty](#)

Please see our model portfolio (Emkay Alpha Portfolio): [SMID](#)

“Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals”

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 04/29/2022 05:57 PM



## Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 29 Apr 2022 02:34:42 (SGT)

Dissemination Date: 29 Apr 2022 02:35:42 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com)

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of April 29, 2022
2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
- Disclosure of previous investment recommendation produced:**
3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of April 29, 2022.
5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the April 29, 2022
6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the April 29, 2022

**RESTRICTIONS ON DISTRIBUTION**

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com